Evidence map›Paper›PMID 41392547›Full record

ArticleBioanalysis2025

Development of an electrochemiluminescence assay to measure serum darbepoetin concentration in extremely preterm infants.

Jessie R Maxwell, Robin K Ohls, Guohua An, Dane Winter, Sandra Beauman, Jonathan Buhrman, Lauren L Jantzie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jessie R MaxwellDivision of Neonatology, Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA.ORCID 0000-0001-8990-7239
Robin K OhlsDivision of Neonatology, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Guohua AnDepartment of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, LA, USA.
Dane WinterSchool of Medicine, University of California, San Diego, CA, USA.
Sandra BeaumanDivision of Neonatology, Department of Pediatrics, University of New Mexico, Albuquerque, NM, USA.
Jonathan BuhrmanMeso Scale Diagnostics, LLC, Rockville, MD, USA.
Lauren L JantzieDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5410-3553

Funding

NICHD Cooperative Multicenter Neonatal Research Network - Utah CenterUG1HD087226 · NICHD · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI ROBIN K OHLS · 2016 to 2026
$3.3M
Eunice Kennedy Shriver NICHD Cooperative Multicenter Neonatal ResearchNetworkUG1HD053089 · NICHD · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Janell Fuller, Jessie R. Maxwell · 2016 to 2026
$3.2M
Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterms-CCCU01HL136318 · NHLBI · UNIVERSITY OF UTAH · PI OHLS, ROBIN K · 2017 to 2021
$1.8M
NHLBI NIH HHS U01 HL136318NICHD NIH HHS UG1 HD053089NICHD NIH HHS UG1 HD087226
6 · The paper itself

Abstract

backgroundThe erythropoiesis stimulating agents (ESAs), erythropoietin (Epo) and darbepoetin (Darbe), are administered clinically to preterm infants to stimulate red cell production and decrease red blood cell transfusions. Darbe is longer acting compared to Epo, allowing for weekly administration; however, Darbe does not have a specific assay to allow for serum measurements. RESEARCH DESIGN AND

methodsWe developed a sensitive and specific electrochemiluminescent assay for future reliable measurement of serum and plasma Darbe concentrations in samples from preterm infants participating in the multicenter randomized Phase III Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants. A multi-array electrochemiluminescence platform was used to develop an immunoassay to quantitatively measure Darbe concentrations in biological fluids.

resultsCapture and detection antibodies were identified, evaluated, and optimized. Assay sensitivity, intra- and inter-plate reproducibility, and specificity were assessed to verify the utility of the assay for the purpose of accurately measuring Darbe in these samples.

conclusionsA reliable and accurate assay to measure Darbe concentrations in serum or plasma was developed and validated on a clinically translatable platform. This method will be applied to quantify Darbe serum concentrations in extremely premature infants and to perform population pharmacokinetic analyses.

Indexed as

Darbepoetin alfaElectrochemical TechniquesInfant, Extremely PrematureLuminescent MeasurementsHumansImmunoassayInfant, NewbornDarbepoetin alfaanemia of prematuritydarbepoetinerythropoiesiserythropoietinPrematurity

Identifiers

PMID41392547
PMCPMC12867447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.